Chief Medical Officer
Brian has more than 20 years of experience in developing precision medicine, especially in the field of oncology.
Prior to joining Cornerstone, Brian was the Global Head of Clinical Affairs, Oncology Precision Medicine / Companion Diagnostics at Novartis; Senior Director, Oncology Translational Medicine at Eli Lilly; Director, Oncology Clinical Development at Bristol-Myers Squibb and Medical Director at Myriad Genetics
At Cornerstone, Brian is responsible for clinical development of Cornerstone’s platform technology. He will guide the clinical development of Cornerstone’s lead compound, CPI-613, as well as the other promising compounds in pipeline.